Dr. Stender is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3577 W 13 Mile Rd
Ste 404
Royal Oak, MI 48073Phone+1 248-551-6900Fax+1 248-551-6909
Education & Training
Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1995 - 1998- Indiana University School of MedicineResidency, Internal Medicine, 1992 - 1995
Wayne State University School of MedicineClass of 1992
Certifications & Licensure
MI State Medical License 1998 - 2026
IN State Medical License 1997 - 2015- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013
- Fellow (FACP) American College of Physicians, 2011
Clinical Trials
- Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Publications & Presentations
PubMed
- 25 citationsFungal infections in hematopoietic stem-cell transplant patients: a review of epidemiology, diagnosis, and management:Mandeep Singh Rahi, Vishal Jindal, Prachi Pednekar, Jay Parekh, Kulothungan Gunasekaran
Therapeutic Advances in Infectious Disease. 2021-08-19 - 11 citationsTherapeutic landscape of advanced HER2-positive breast cancer in 2022.Ruby Gupta, Sachin Gupta, Bana Antonios, Bipin Ghimire, Vishal Jindal
Medical Oncology. 2022-10-12 - 105 citationsPhase II Trial of Gemcitabine in Refractory Germ Cell TumorsLawrence H. Einhorn, Michael J. Stender, Stephen D. Williams
Journal of Clinical Oncology. 1999-02-01
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
